1. Identification of DAXX as a restriction factor of SARS-CoV-2 through a CRISPR/Cas9 screen.
- Author
-
Mac Kain, Alice, Maarifi, Ghizlane, Aicher, Sophie-Marie, Arhel, Nathalie, Baidaliuk, Artem, Munier, Sandie, Donati, Flora, Vallet, Thomas, Tran, Quang, Hardy, Alexandra, Chazal, Maxime, Porrot, Françoise, OhAinle, Molly, Carlson-Stevermer, Jared, Oki, Jennifer, Holden, Kevin, Zimmer, Gert, Simon-Lorière, Etienne, Bruel, Timothée, Schwartz, Olivier, van der Werf, Sylvie, Jouvenet, Nolwenn, Nisole, Sébastien, Vignuzzi, Marco, and Roesch, Ferdinand
- Subjects
COVID-19 ,CRISPR-Cas Systems ,Co-Repressor Proteins ,Humans ,Interferons ,Molecular Chaperones ,Proteasome Endopeptidase Complex ,SARS-CoV-2 - Abstract
Interferon restricts SARS-CoV-2 replication in cell culture, but only a handful of Interferon Stimulated Genes with antiviral activity against SARS-CoV-2 have been identified. Here, we describe a functional CRISPR/Cas9 screen aiming at identifying SARS-CoV-2 restriction factors. We identify DAXX, a scaffold protein residing in PML nuclear bodies known to limit the replication of DNA viruses and retroviruses, as a potent inhibitor of SARS-CoV-2 and SARS-CoV replication in human cells. Basal expression of DAXX is sufficient to limit the replication of SARS-CoV-2, and DAXX over-expression further restricts infection. DAXX restricts an early, post-entry step of the SARS-CoV-2 life cycle. DAXX-mediated restriction of SARS-CoV-2 is independent of the SUMOylation pathway but dependent on its D/E domain, also necessary for its protein-folding activity. SARS-CoV-2 infection triggers the re-localization of DAXX to cytoplasmic sites and promotes its degradation. Mechanistically, this process is mediated by the viral papain-like protease (PLpro) and the proteasome. Together, these results demonstrate that DAXX restricts SARS-CoV-2, which in turn has evolved a mechanism to counteract its action.
- Published
- 2022